# Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

> **NCT03715985** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Herlev Hospital** · enrollment: 12 (actual)

## Conditions studied

- Malignant Melanoma, Metastatic
- Non Small Cell Lung Cancer Metastatic
- Bladder Urothelial Carcinoma, Metastatic

## Interventions

- **DRUG:** EVAX-01-CAF09b

## Key facts

- **NCT ID:** NCT03715985
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-28
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715985, "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03715985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*